Endocrine disease research, peptide therapeutics, and biotech innovation by MBX Biosciences
MBX Biosciences, Inc. partners with HypoPARAassoc to advance treatment for over 100,000 hypoparathyroidism patients in U.S.
MBX Biosciences, Inc. announced a partnership with HypoPARAassoc focused on accelerating progress for over 100,000 people in the U.S. affected by hypoparathyroidism, a rare endocrine disorder. ...
MBX Biosciences, Inc. executives to update on endocrine and metabolic disorder treatment advancements in New York
MBX Biosciences, Inc. will participate in the Jefferies 2026 Global Healthcare Conference in New York City on June 3. Chief Executive Officer Kent Hawryluk and Chief Medical Officer Sam Azoulay, ...
MBX Biosciences, Inc. thanks clinical trial participants as new therapies progress
MBX Biosciences, Inc. has acknowledged the vital role of researchers and patients participating in clinical trials, emphasizing their contributions on Clinical Trials Day. The company stated that ...
Obesity portfolio update features new clinical data from MBX Biosciences, Inc.
MBX Biosciences, Inc. announced it will present updates on its obesity portfolio at Obesity Day, including the first Phase 1 clinical data for MBX 4291, a GLP 1 GIP co agonist. The announcement ...
MBX Biosciences, Inc. focuses on science-led innovation to transform endocrine and metabolic disease treatment
MBX Biosciences, Inc. has reaffirmed its commitment to science-driven innovation in recognition of World Health Day. The company is leveraging its proprietary PEP Platform to reshape the treatment ...
Executives to engage with investors at key biotech events, MBX Biosciences outlines
MBX Biosciences, Inc. announced that Chief Executive Kent Hawryluk and Chief Medical Officer Sam Azoulay will meet investors at the Jefferies Biotech on the Beach Summit and participate in a ...
MBX Biosciences, Inc. completes End-of-Phase 2 FDA meeting for chronic hypoparathyroidism therapy
MBX Biosciences, Inc. has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding its once-weekly investigational therapy for chronic ...
MBX Biosciences thanks staff for dedication and collaboration, MBX Biosciences asserts
MBX Biosciences, Inc. Chief Human Resource Officer Michelle Graham publicly thanked the company's workforce in recognition of Employee Appreciation Day. Graham emphasized the impact of employees' ...
MBX Biosciences CEO and CMO join key investor events at Citizens Bank conference and UBS Biotech Summit
MBX Biosciences, Inc. announced that its CEO, Kent Hawryluk, and Chief Medical Officer, Sam Azoulay, MD, will participate in a fireside chat at the Citizens Bank Life Sciences Conference next ...
